These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

789 related items for PubMed ID: 18721768

  • 21. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.
    Russell N, Douglas K, Ho AD, Mohty M, Carlson K, Ossenkoppele GJ, Milone G, Pareja MO, Shaheen D, Willemsen A, Whitaker N, Chabannon C.
    Haematologica; 2013 Feb; 98(2):172-8. PubMed ID: 22983579
    [Abstract] [Full Text] [Related]

  • 22. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
    Li J, Hamilton E, Vaughn L, Graiser M, Renfroe H, Lechowicz MJ, Langston A, Prichard JM, Anderson D, Gleason C, Lonial S, Flowers CR, Kaufman JL, Waller EK.
    Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
    [Abstract] [Full Text] [Related]

  • 23. Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost.
    Boeve S, Strupeck J, Creech S, Stiff PJ.
    Bone Marrow Transplant; 2004 May; 33(10):997-1003. PubMed ID: 15064690
    [Abstract] [Full Text] [Related]

  • 24. A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor.
    Abhyankar S, DeJarnette S, Aljitawi O, Ganguly S, Merkel D, McGuirk J.
    Bone Marrow Transplant; 2012 Apr; 47(4):483-7. PubMed ID: 21725372
    [Abstract] [Full Text] [Related]

  • 25. [Efficiency and safety analysis of Plerixafor combined with granulocyte colony-stimulating factor on autologous hematopoietic stem cell mobilization in lymphoma].
    Ji MM, Shen YG, Gong JC, Tang W, Xu XQ, Zheng Z, Chen SY, He Y, Zheng X, Zhao LD, Zhao WL, Wu W.
    Zhonghua Xue Ye Xue Za Zhi; 2023 Feb 14; 44(2):112-117. PubMed ID: 36948864
    [Abstract] [Full Text] [Related]

  • 26. Mobilization strategies in hard-to-mobilize patients with lymphoid malignancies.
    Jantunen E, Kvalheim G.
    Eur J Haematol; 2010 Dec 14; 85(6):463-71. PubMed ID: 20738393
    [Abstract] [Full Text] [Related]

  • 27. [Effectiveness of plerixafor in patients undergoing mobilization autologous haematopoietic progenitor cell].
    Ruano Camps R, Ortiz Pareja M, Vidales Mancha I, Muñoz Castillo IM, Heiniger Mazo AI.
    Farm Hosp; 2013 Dec 14; 37(4):317-21. PubMed ID: 24010693
    [Abstract] [Full Text] [Related]

  • 28. Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte-colony stimulating factor plus plerixafor in patients with β-thalassemia major.
    Yannaki E, Karponi G, Zervou F, Constantinou V, Bouinta A, Tachynopoulou V, Kotta K, Jonlin E, Papayannopoulou T, Anagnostopoulos A, Stamatoyannopoulos G.
    Hum Gene Ther; 2013 Oct 14; 24(10):852-60. PubMed ID: 24001178
    [Abstract] [Full Text] [Related]

  • 29. No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF.
    Gazitt Y, Akay C, Thomas C.
    Stem Cells Dev; 2006 Apr 14; 15(2):269-77. PubMed ID: 16646673
    [Abstract] [Full Text] [Related]

  • 30. FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation.
    Brave M, Farrell A, Ching Lin S, Ocheltree T, Pope Miksinski S, Lee SL, Saber H, Fourie J, Tornoe C, Booth B, Yuan W, He K, Justice R, Pazdur R.
    Oncology; 2010 Apr 14; 78(3-4):282-8. PubMed ID: 20530974
    [Abstract] [Full Text] [Related]

  • 31. Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.
    Spoerl S, Peter R, Wäscher D, Götze K, Verbeek M, Peschel C, Krackhardt AM.
    Transfusion; 2017 Jan 14; 57(1):115-121. PubMed ID: 27859332
    [Abstract] [Full Text] [Related]

  • 32. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
    Koç ON, Gerson SL, Cooper BW, Laughlin M, Meyerson H, Kutteh L, Fox RM, Szekely EM, Tainer N, Lazarus HM.
    J Clin Oncol; 2000 May 14; 18(9):1824-30. PubMed ID: 10784622
    [Abstract] [Full Text] [Related]

  • 33. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.
    Fruehauf S, Ehninger G, Hübel K, Topaly J, Goldschmidt H, Ho AD, Müller S, Moos M, Badel K, Calandra G.
    Bone Marrow Transplant; 2010 Feb 14; 45(2):269-75. PubMed ID: 19597422
    [Abstract] [Full Text] [Related]

  • 34. Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization.
    Yuan S, Nademanee A, Kaniewski M, Palmer J, Shayani S, Wang S.
    Transfusion; 2014 Aug 14; 54(8):2015-21. PubMed ID: 24660786
    [Abstract] [Full Text] [Related]

  • 35. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
    Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, Craig M, Hamadani M.
    J Clin Apher; 2013 Oct 14; 28(5):359-67. PubMed ID: 23765597
    [Abstract] [Full Text] [Related]

  • 36. Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.
    Veltri L, Cumpston A, Shillingburg A, Wen S, Luo J, Leadmon S, Watkins K, Craig M, Hamadani M, Kanate AS.
    Cytotherapy; 2015 Dec 14; 17(12):1785-92. PubMed ID: 26475754
    [Abstract] [Full Text] [Related]

  • 37. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.
    Maziarz RT, Nademanee AP, Micallef IN, Stiff PJ, Calandra G, Angell J, Dipersio JF, Bolwell BJ.
    Biol Blood Marrow Transplant; 2013 Apr 14; 19(4):670-5. PubMed ID: 23333777
    [Abstract] [Full Text] [Related]

  • 38. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.
    Farina L, Spina F, Guidetti A, Longoni P, Ravagnani F, Dodero A, Montefusco V, Carlo-Stella C, Corradini P.
    Leuk Lymphoma; 2014 Feb 14; 55(2):331-6. PubMed ID: 23656194
    [Abstract] [Full Text] [Related]

  • 39. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.
    Attolico I, Pavone V, Ostuni A, Rossini B, Musso M, Crescimanno A, Martino M, Iacopino P, Milone G, Tedeschi P, Coluzzi S, Nuccorini R, Pascale S, Di Nardo E, Olivieri A.
    Biol Blood Marrow Transplant; 2012 Feb 14; 18(2):241-9. PubMed ID: 21791194
    [Abstract] [Full Text] [Related]

  • 40. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET, Towery JA, Miller AN, Kramer C, Hogan KR, Squires JE, Stuart RK, Costa LJ.
    Transfusion; 2011 Sep 14; 51(9):1995-2000. PubMed ID: 21392017
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 40.